Colgate-Palmolive Company (NYSE: CL) — Global Repair Outruns the U.S. Reset

Published: 2026-10-31 · Verdict: Hold · Entry price: $85 · Research confidence: High (82%)

Executive conclusion

Analyst Take

HOLD at $95.29, the October 30, 2026 close. Colgate-Palmolive’s operating outlook improved again, but the price already requires sustained cash compounding. My evidence-contingent accumulation framework remains approximately $83–87, centered on $85. That midpoint is about 21.7 times the $3.91 midpoint implied by updated 2026 Base Business EPS guidance. It is a valuation judgment, not a forecast of a trading low. The August report’s $78–85 range was reached in early October; acknowledging that outcome does not imply that a position was established. S1 S13

The central change is a broader recovery in demand. Third-quarter organic sales increased 3.6%, including 1.7% organic volume growth. Hill’s returned to positive volume, and emerging-market volume remained strong. Base gross margin expanded 90 basis points despite significant material inflation. These results challenge the prior expectation that the second-half cost peak would necessarily reverse the margin recovery. Management raised annual gross-margin guidance and now expects 5–7% Base EPS growth. The investment case should incorporate those improvements rather than preserve a bearish operating narrative after contrary evidence arrives. [S1][S4]

The qualification is the economics of defending and rebuilding demand. North American Oral, Personal and Home Care volume declined 3.7%, regional operating profit fell 11%, and management reported no meaningful retailer destocking. That makes the region’s weakness harder to dismiss as shipment timing. Advertising increased about 15% in the quarter, while Asia Pacific and Hill’s both reported lower regional operating margins despite sales growth. Global growth is improving faster than the conversion of that growth into retained margins. The key question is how much future support creates durable demand, and how much becomes the recurring cost of maintaining existing preference. [S2][S5]

My variant perception is therefore two-sided. The global operating recovery deserves more credit than the August caution allowed. The claim that Colgate is uniquely out-executing its competitive set deserves less. P&G’s volume recovered, Church & Dwight delivered faster organic growth and stronger quarterly profit growth, Haleon’s Oral Health business grew 8.8%, and Nestlé Petcare delivered positive underlying growth. These observations do not erase Colgate’s advantages. They establish that the company must earn its premium against capable competitors, including specialists attacking the premium oral and pet segments it wants to grow. [S15][S16][S17][S18]

The strongest counter-case to this measured stance is that Colgate is already demonstrating the required operating resilience. Productivity and pricing offset substantial inflation; Hill’s improved before U.S. fresh food became material; and net debt declined. If North America stabilizes, existing global growth can support better consolidated earnings without a major acquisition or another exceptional capacity program. Waiting for complete confirmation may mean paying more for an improvement that was visible earlier. That argument has strengthened since August, particularly because the correct year-ago gross-margin comparison shows expansion rather than deterioration. [S2][S4]

Valuation and cash temper that argument. The shares trade at approximately 24.4 times guided 2026 Base EPS and 16.0 times a trailing adjusted EBITDA proxy. Consolidated conventional FCF yields about 5.0%, but that cash includes minority interests and adds back compensation paid in equity. A more cautious normalized owner-cash assumption is $3.3 billion, materially below consolidated FCF of $3.789 billion. Under the explicit central assumptions developed below, the cash valuation is around $91 per share; reasonable bear and bull assumptions span approximately $61–123. Those are scenario outputs, not targets. The current quotation requires about 4.6% annual aggregate owner-cash growth under the specified central discount and terminal conventions. [S2][S3][S13]

Investment conviction is moderate; confidence in reported operating improvement is higher than confidence in the U.S. recovery timetable, advertising returns or normalized cash. The next decision sequence is Q4 cost and payment execution, initial 2027 guidance, and repeated North American purchase and contribution evidence. Two consecutive quarters of positive regional organic volume with stable profitability, continuing Hill’s branded volume and improving cash after actual restructuring payments would strengthen the call. Continued U.S. contraction without destocking, another expansion in restructuring costs, or a material deterioration in legal exposure would weaken it. These are analyst tests, not promises by management.

Changes since 2026-08-22

The prior report’s near-term margin concern encountered contrary evidence. Q3 GAAP gross margin was 60.2%, versus 59.4%, and Base margin was 60.3%. The earlier report’s 61.0% year-ago comparator was wrong. Sequential margin declined from Q2’s 61.5%, but year-over-year margin expanded. Those are different comparisons and should not be combined into one judgment. [S1][S10]

Hill’s no longer fits a price-only description: organic volume increased 1.8%, or 2.5% excluding the private-label exit in official prepared remarks. Developed-market volume also became slightly positive. North American weakness remained, but the latest management statement removes meaningful destocking as the principal explanation for this quarter. Advertising returns, sustained U.S. recovery and growth through unfavorable currency remain unresolved. [S1][S4][S5]

Restructuring charges slowed materially in Q3 while cash payments exceeded new charges. The latest filing discloses $346 million program-to-date charges, $76 million quarterly payments and a $172 million ending accrual. First-half charges should not be extrapolated as a recurring half-year run rate. A small arithmetic inconsistency remains between the two quarterly filings’ cumulative and standalone charge disclosures; the report uses each disclosed period directly and does not conceal it with a forced reconciliation. [S2][S10]

The acquisition record requires a larger correction: the prior report omitted the $721 million pretax 2022 Filorga impairment between the 2021 and 2025 charges. Its implication that the acquisition’s economic downside was effectively closed is unsupported. Talc cases increased to 561 from 453 at year-end. Recent small settlements do not bound the future legal tail. [S2][S8][S9]

The stock increased 4.6% from the August reference price before dividends. The prior accumulation range was reached on October 1–5, including an $83.99 intraday low on October 2. Historical prices below use an unadjusted series consistently; dividend-adjusted historical extrema are not mixed into the same event map. [S13]

Stock Price Action — Five-Year Event Map

Company Financials supplied 1,256 unadjusted daily observations from October 29, 2021 through October 30, 2026. The first close was $76.19 and the latest $95.29, approximately 25.1% appreciation, or 4.6% annually before dividends. The five-year intraday low was $67.62 on October 6, 2023; the high was $109.30 on September 5, 2024. The latest 52-week range was $74.545–99.33. The current quotation is 4.1% below the annual high and 12.8% below the five-year high. Recent daily prices were independently cross-checked. S13

CL’s October 22 gain of 4.27% occurred on P&G’s reporting day. Over the full August 21–October 30 window, CL gained 4.62%, versus 11.67% for PG and 8.53% for CHD. These are price returns with matched endpoints, excluding dividends. They challenge the claim that CL’s recent advance proves exceptional company-specific performance. They do not identify what proportion of any return was caused by sector allocation. The two peers have different categories, geography and announcement calendars. [S13][S25][S26]

The October 30 close rose 2.29%, consistent with a favorable response to CL’s results. However, the opening price was $98.00 and the stock finished below it. That intraday pattern supports neither an unqualified enthusiasm narrative nor a claim that the market rejected the results. Closing returns, opening gaps and total returns answer different questions. Dividend adjustments also change old prices as subsequent distributions accumulate, explaining some differences from the prior event map without implying that historical trades changed. [S13]

Verdict: The quotation recovered from an October trough as operating evidence improved. Relative performance and the shared October 22 move prevent treating the rebound as proof that the U.S. problem is solved.

Business Overview

The business is readily understandable: sell trusted replenishment products, then retain enough gross profit to fund availability, innovation and demand support. Oral care, personal hygiene, household cleaning and pet nutrition address recurring needs. The economic complexity lies in brand selection, product mix, retailer terms and execution across countries. Consumption is relatively predictable; which supplier captures it and how much cash remains are less predictable. S3

The annual product mix was 44% Oral Care, 17% Personal Care, 16% Home Care and 23% Pet Nutrition. Product categories differ from reportable operating segments: the current structure comprises four geographic Oral, Personal and Home Care divisions plus Hill’s. Oral care concentrates the portfolio in a category where health claims, trusted performance and habit matter. Pet nutrition provides another source of professional influence. Some cleaning and personal-care products have weaker differentiation, so consolidated economics should not be attributed entirely to toothpaste. [S3][S27]

Customer value and purchase behavior

In toothpaste, consumers buy a combination of cleaning efficacy, prevention, taste, sensitivity management, whitening and reassurance. A product must work sufficiently well, feel acceptable and remain easy to find. The amount spent per purchase is small relative to the perceived consequence of oral-health problems, which can support brand persistence. That persistence is an analytical explanation, not evidence that every customer is captive or insensitive to price. A larger price gap, disliked reformulation or superior competing proposition can change behavior.

Premium oral care creates value when a benefit is both credible and perceptible. Sensitivity relief, gum health and whitening offer different reasons to pay more than a basic paste. The investment question is whether incremental realization exceeds development, claims substantiation, promotion and cannibalization costs. A premium launch can raise average selling price while recruiting few new users. Conversely, an affordable pack can recruit consumption but initially dilute mix. Unit growth and price growth therefore need interpretation alongside contribution.

Hill’s combines everyday wellness food with therapeutic nutrition. Science Diet addresses routine feeding, while Prescription Diet supports particular nutritional needs. A veterinarian’s recommendation can influence initial selection and continued use, creating a demand mechanism that differs from television advertising alone. Nevertheless, veterinarians can recommend competing diets and owners can switch, mix foods or change portion size. The franchise depends on credibility and product suitability rather than pharmaceutical-style legal exclusivity. [S3][S4]

Home and personal care rely on familiar brands including Palmolive, Softsoap, Irish Spring, Sanex, Fabuloso and Suavitel. Performance, fragrance, format, pack size and availability all matter. Their economics vary: a surface cleaner with easy functional substitution should not receive the same switching-cost assumption as a therapeutic pet diet. Selling several products through shared distribution can improve efficiency, but portfolio breadth can also obscure weak individual franchises.

Revenue is recurring through consumption, while most purchases remain transactional and uncontracted. There is no material subscription backlog protecting the next toothpaste sale. Consumers can trade down, buy smaller packs or wait for a promotion. Retailer inventories add another layer between household consumption and manufacturer shipments. Demand resilience reduces cyclicality; it does not make quarterly revenue, market share or cash conversion invariant. [S3][S28]

Divisional economics and reporting boundaries

These are rounded filing amounts; reported margins need not reproduce exactly from rounded sales and profit. Corporate costs reconcile the $1.309 billion sum of divisional profit to $1.088 billion consolidated GAAP operating profit. Research, stock compensation, centrally controlled restructuring and other corporate costs are not fully allocated to the divisions. Regional margins measure contribution, not standalone owner cash or acquisition returns. [S1][S2]

Latin America generated more than twice North America’s operating profit in Q3. The difference illustrates why consumer purchasing power alone does not determine supplier profitability. Brand position, distribution density, product mix and local price architecture can outweigh the average income of the consumer. It also makes Latin America an important source of earnings sensitivity to currencies and local economic conditions. International breadth spreads risk across markets while creating translation and execution exposures.

The North America line does not encompass all U.S. sales. Hill’s is reported separately, and Skin Health moved to EMEA under the 2026 reporting structure. In 2025, U.S. Oral, Personal and Home Care sales were $3.596 billion and U.S. Pet Nutrition sales $3.062 billion. Their combined share was about one-third of consolidated revenue. Calling the whole U.S. business a shrinking annuity exaggerates the scope of the regional weakness and ignores the separate nutrition franchise. [S3][S27]

Distribution, manufacturing and economic assets

Walmart and affiliates represented approximately 11% of annual sales. Other routes include grocers, distributors, pet-specialty retailers, professional channels and e-commerce. Retailers provide access and consumer data; Colgate brings brands, traffic and category innovation. These assets create bilateral bargaining power. A strong brand can resist some demands, but it still needs acceptable retailer economics, service and shelf productivity. [S3]

Manufacturing and procurement operate across countries. That supports local availability, regional sourcing and spreading technical capabilities across large volumes. Production is economically important, but manufacturing a competent toothpaste is easier than establishing repeated consumer preference and distribution. Supplier qualification and quality consistency remain constraints, particularly where materials have limited qualified sources. Global scale is useful without being sufficient to guarantee local demand.

The principal unrecognized assets are internally built brands, professional relationships, distribution access and formulation know-how. Their creation costs largely passed through income. Purchased brands and goodwill appear on the balance sheet, producing an asymmetry between built and acquired franchises. Book capital consequently understates some internal investment while potentially retaining an acquisition price that later proves excessive. Neither low book value nor high goodwill alone establishes competitive advantage. [S3]

CL is ordinary U.S. corporate common stock, not an ADR, partnership or K-1 security. The listed issuer is a Delaware corporation. The appropriate analytical claim is ownership of a residual corporate cash stream after creditors, subsidiary minorities and reinvestment. Individual holders’ tax treatment depends on their circumstances; no partnership distribution model is needed. [S2]

Verdict: Replenishment demand, oral-health concentration and specialty nutrition support durable economics. The model’s resilience must still be expressed through repeated brand choice, retailer access and retained contribution in each market.

Industry Dynamics

The operating peer set follows products. P&G’s Crest and Oral-B compete in oral care; Haleon’s Sensodyne and parodontax are particularly relevant to premium benefits; Church & Dwight overlaps through TheraBreath, Arm & Hammer and Waterpik. Nestlé Purina and Mars/Royal Canin matter directly to Hill’s. Freshpet represents a different manufacturing and distribution model competing for some of the same feeding occasions. These competitors are identified from current company materials, rather than a broad stock-market taxonomy. [S16][S18][S29][S31][S32][S33]

Category growth, geography and profit pools

Demand is global: roughly two-thirds of Colgate’s sales come from outside the United States and approximately 45% from emerging markets. The categories collectively exceed CL’s revenue base, but the reviewed evidence does not provide a reconciled, consistently defined global addressable-market total. Applying toothpaste share to all oral-care revenue would be a denominator error because toothbrushes, mouthwash and other products have different category sizes and coverage. [S2]

Management estimates current global category growth at approximately 1.5–3%, with emerging markets around 3–5%. These are management assessments of relevant categories, not independently audited market forecasts. The broad conclusion is modest, uneven growth. Mature oral-care markets depend more on premium benefits, frequency and mix; lower-consumption markets can also grow through penetration and availability. Pet nutrition differs by species, life stage, medical need and food format. A single global growth assumption misses these distinctions. [S5]

Profit pools are correspondingly uneven. Basic cleaning products face functional substitution and promotion. Premium oral health can support higher realization because consumers value an identifiable health benefit. Therapeutic nutrition combines recurring feeding with recommendation and formulation credibility. These characteristics can support high incumbent returns, but attractive demand also encourages competitors to invest. Current Haleon and Nestlé results show that premium oral and pet opportunities are shared by several capable suppliers. [S17][S18]

Incumbent profitability rests on brands, professional advocacy, distribution density and the ability to spread recurring commercial investment. Manufacturing capacity alone is an incomplete barrier. A new entrant must create repeat use, obtain access, meet quality requirements and finance awareness. The scale threshold differs by channel: a small digital brand can establish a niche before building mass retail distribution. The multinational advantage emerges when it converts research, procurement, local distribution and marketing into better unit economics across substantial volume. [S3][S31][S33]

Competitive intensity and the premium contest

Competitive intensity is increasing in selected developed-market categories, although it is not uniform across products or countries. Colgate’s September conference described selective couponing, retailer-program gaps and a multiyear North American reset. Current performance also supplies a less comfortable competitive benchmark: Haleon’s Oral Health revenue increased 8.8%, while Church & Dwight’s consolidated organic growth was 5.1% with 4.6% volume. These measures are not category-matched market-share calculations, but they disprove the idea that competitors are uniformly stalled. [S16][S17][S22]

P&G’s latest 4.0% organic growth included positive consolidated volume, but its Health Care segment’s organic volume declined 2.9%. The segment includes more than oral care, so that decline cannot be assigned directly to Crest. Equally, P&G’s overall volume recovery cannot prove that every competing oral brand improved. This distinction matters when evaluating the prior report’s broad claims about the two largest incumbents. Whole-company comparisons can inform financial context while remaining poor evidence of category share. [S15]

Private label is a differentiated threat. It is more persuasive where consumers regard products as interchangeable and retailers can offer a visible saving. Health-related claims, familiar sensory experience and professional advice can support branded preference, but none creates unlimited pricing power. The practical risk is often a better price-value proposition supported by strong distribution, rather than a technically inferior product winning solely because it is cheap.

Retail media and e-commerce also alter the commercial cost structure. Retailers control search placement, first-party shopper data and portions of online discovery. Brands may have to fund both traditional consumer advertising and platform-specific visibility. A company can improve content production efficiency while paying more for access to the consumer. That creates a plausible mechanism for higher maintenance marketing costs even when physical manufacturing remains efficient. The mechanism must be tested in margins and repeat demand rather than assumed from technology adoption.

Supply-side capital cycle

In core toothpaste and household products, consumer preference is scarcer than manufacturing capacity. A new production line does not automatically recruit customers. The more relevant continuing investments are formulation, brand support, promotion and retailer relationships. Consequently, the absence of a factory-building boom does not establish rational competition. Companies can compete away returns through selling expense or acquisition prices without constructing excessive physical capacity.

Pet nutrition has a more visible capacity dimension. Dry, wet and refrigerated products require different equipment, service and inventory systems. Colgate’s 2022 purchases of pet manufacturing businesses, alongside subsequent investment, committed capital before all prospective volume arrived. The current growth in wet and therapeutic products can improve utilization of that installed base. The return should include purchase consideration and follow-on spending, not merely today’s lower capex ratio. [S8][S4]

Freshpet’s filing makes the full-system issue concrete: its model requires installed retail refrigerators and a dedicated production and distribution system. That is relevant to the economics of fresh nutrition, even though Hill’s uses a different channel mix and rollout. Faster category growth can attract incremental manufacturing and cold space; retailers and advertisers may capture part of the resulting economics. A phased launch can reduce execution risk, but public disclosures do not yet establish Hill’s fresh-food return on invested capital. [S29]

Acquisitions offer another outlet for capital attracted by high category returns. Buyers may pay for an appealing adjacency before demonstrating that their existing capabilities transfer. Filorga’s repeated impairments are evidence that attractive core economics do not guarantee attractive purchased growth. The correct capital-cycle question therefore includes the price paid for brands and capabilities, rather than only industry’s physical supply.

Regulation, low-cost production and operating constraints

Low-cost foreign production is a secondary threat relative to quality, trusted claims, local availability and effective distribution. Colgate already participates in international sourcing and manufacturing. The more dangerous competitor combines acceptable performance, attractive pricing and channel execution. Tariffs can still disrupt this network, and replacing a qualified ingredient source can take time. An international footprint is a risk-management capability, not immunity to trade friction. [S3]

Regulation covers ingredients, product safety, labeling, advertising claims, manufacturing, competition, privacy and taxation. Requirements vary with the product and its claims. Pet nutrition adds animal-food safety and labeling obligations. Compliance creates recurring cost and qualification barriers, but does not grant broad monopoly rights. The annual filing says no single patent is significant to the business as a whole. The franchise is therefore more dependent on repeated execution than patent expiry schedules. [S3]

Legal exposure also extends beyond current products. Historic talc claims can create cash obligations after the associated products cease contributing revenue. The industry’s health and trust positioning makes quality failures asymmetric: a small short-term saving can damage a much larger stream of future demand. Regulation belongs in operating and capital economics wherever it affects cost, access or liabilities; describing it generically as light obscures these channels.

Verdict: Oral health and therapeutic nutrition support favorable incumbent economics, but capable competitors are investing in the same premium opportunities. The binding supply-side risks are commercial spending, acquired capital and format-specific capacity, alongside ordinary manufacturing.

Competitive Position

Colgate’s advantage combines consumer trust, professional credibility, local distribution and global capabilities. The thesis is strongest where these mechanisms jointly preserve volume, realization and profit after support. A global leadership label is not sufficient. The same organization can earn attractive returns in one region while spending heavily to repair another, and recent results make that geographic distinction economically important. [S1][S4]

Brands matter economically only while they preserve preference, realization and retained profit after advertising. Company-reported year-to-date global toothpaste value share was 41.4% and manual-toothbrush share 33.1%. These support category leadership, but the measures combine external data and internal estimates, cover specified markets and channels, and generally lag current trading. They are useful indicators rather than a complete independently verified census. [S1]

Evidence by geography

Latin America supplies the clearest current combination of growth and retention. Q3 organic sales increased 6.0%, volume 3.9%, and regional operating profit 17%. Its reported margin reached 29.6%. On the recast nine-month perimeter, profit increased from $1.052 billion to $1.211 billion. These outcomes are consistent with effective brand positioning and distribution. They are stronger evidence than revenue alone because the company retained a substantial share of incremental sales before Corporate costs. [S1][S2]

The counterargument is that favorable currency and regional conditions also help. Management described strong Brazil execution but a harder Mexican environment and retailer-specific issues. The regional result should not be extended to every country. A broad moat claim is most credible when gains persist across currency conditions, local inflation and different retailer settings. The latest quarter supports the mechanism; it does not settle its full duration.

EMEA combined 3.5% volume growth with 2.7% organic growth and a 140-basis-point regional margin increase. Management separately described premium oral progress and share gains. The separate evidence matters: volume growth with negative pricing does not itself establish market-share gains. Lower realized prices can stimulate units without improving relative preference. Retained profit and independent category comparison are the relevant additional tests. [S1][S4]

The prior European shorthand was also too broad. Q2’s negative EMEA pricing was attributed in official remarks primarily to Skin Health, especially China. A consolidated geographic price measure therefore cannot prove that European premium toothpaste grew because prices were cut. Products, countries and reporting boundaries must match before inferring elasticity or competitive advantage. This correction strengthens the analytical test even while the region’s reported performance remains favorable. [S28]

Asia Pacific shows the difference between sales recovery and stronger economic returns. Organic sales increased 4.6%, but regional operating profit declined approximately 1% and margin fell 110 basis points. India and Colgate China performed well according to management; Hawley & Hazel remained in the process of improvement. Higher growth can coexist with pressure from support spending, mix or costs. Investors should require profit conversion before treating every sales recovery as a stronger moat. [S1][S4][S5]

North America is the strongest disconfirming observation. Negative volume, weaker contribution and the absence of meaningful destocking undermine a simple temporary-inventory explanation. Early toothpaste share progress can coexist with weakness in other products or channels. A measured share improvement is encouraging, but the more demanding result is a region that recruits demand and retains profit after spending. That result has not yet appeared consistently. [S2][S5]

Switching costs and professional influence

Consumers face minimal contractual switching costs; habit, trust and professional recommendation create behavioral persistence. A toothpaste buyer can change brands immediately. A pet owner may be more reluctant to alter a veterinarian-recommended diet because of an animal’s response, routine or health condition. Those frictions are economically useful but reversible. They do not resemble a technical system that becomes unusable after switching suppliers. [S3][S33]

Professional influence can reduce reliance on broad shelf promotion when recommendation follows perceived suitability. It can also impose an unusually high quality threshold. A serious product failure risks damaging both consumer trust and the confidence of professionals who recommend it. The mechanism is therefore double-edged: recommendation can stabilize demand, while loss of credibility can propagate beyond a single purchase.

Hill’s current therapeutic, cat and wet-food strength is consistent with its stated scientific strategy. However, Nestlé’s positive Petcare underlying growth and Mars’s science-led portfolio show that this channel contains credible alternatives. The correct claim is differentiated competitive participation, not sole ownership of veterinary authority. Professional relationships must continue to produce recommendation, availability and repeat feeding at acceptable economics. [S4][S18][S33]

Nature of competition and scale

Competition combines science, claims, product performance, price-pack architecture, promotion, professional advice and channel execution. Functional premiumization is attractive when users perceive a benefit and continue paying after introductory support. Novelty alone can generate trial without durable contribution. Reported price and mix cannot identify which mechanism dominates; repeat purchase and sustained profit are better tests. [S3][S16][S32]

Global capabilities have genuine potential cost value. Research can support multiple markets, procurement can aggregate demand, and manufacturing standards can be shared. Local execution determines how much of that value is realized. The previous assertion that global scale has no meaningful cost advantage was too categorical. Equally, a multinational brand does not automatically possess the right local assortment, promotion or digital content.

The most useful moat scorecard combines four outcomes: persistent category-relative demand, acceptable realized pricing, stable contribution after support and attractive returns on all committed capital. Each protects against a different false positive. Units purchased through discounting need a margin test; premium pricing needs a buyer-retention test; high margins need an investment-capital test; and strong aggregate returns need segment scrutiny.

Advertising cannot be assigned a causal return from the disclosed quarterly correlations. More spending alongside higher volume is consistent with effective investment, but new products, competitors, category growth and comparisons change simultaneously. Management says measured returns justify support; public disclosures do not provide the cohort-level contribution bridge needed to independently quantify it. Conversely, spending above 14% of sales does not prove waste. The appropriate skeptical position is to require persistent outcomes rather than assume either success or failure.

Verdict: The advantage remains durable but uneven. Latin America and EMEA demonstrate effective retention; Hill’s shows renewed demand; North America and Asia’s weaker profit conversion establish important limits. The moat must be valued after its maintenance costs.

Growth History and Forward Opportunities

Annual sales rose from $17.421 billion in 2021 to $20.382 billion in 2025, approximately 4.0% compound growth. Organic growth was 4.4%, 7.0%, 8.4%, 7.4% and 1.4% across those years. The inflation period included substantial price recovery; it should not be treated as a stable unit-growth trajectory. The 2025 slowdown exposed how much of the earlier growth depended on pricing rather than consumption. [S3][S6][S7][S8][S9]

Components are rounded and need not sum exactly. Acquisition-related volume is excluded from organic volume; discontinued private-label activity remains in the company’s organic comparison. Nine-month currency support was approximately 2.8 percentage points, versus 1.0 point in Q3. Thus the recovery is increasingly supported by volume, while reported growth still benefits from translation. [S1][S11][S28]

The product outlook improved beyond a purely price-led profile, with emerging markets and Hill’s providing the strongest current evidence. The U.S. premium reset and fresh-food expansion remain less established. The growth case does not require every opportunity to succeed, but it requires enough incremental demand to cover increased commercial support and ordinary reinvestment. [S4][S5]

Emerging markets and premium recruitment

Nine-month emerging-market organic sales increased 5.4%, including 3.3% volume. This supports the earlier hypothesis that consumption and premiumization can generate demand beyond inflation recovery. The opportunity varies by market: distribution and affordability recruit use where consumption is low, while functional innovation can raise value per use in more developed categories. [S1]

Pack architecture creates tradeoffs. A smaller package can improve affordability at checkout while raising price per unit; a larger value pack can lower realization while increasing frequency or retention. Neither is automatically superior. The useful outcome is more lifetime contribution from a retained household, rather than one quarter’s maximum price or volume. Public segment data cannot isolate that household-level economics, so the investment thesis must use repeated aggregate outcomes.

India and China illustrate different execution requirements. Modern trade, rural distribution, e-commerce and social platforms demand different product and content choices. Management’s strong India and Colgate China commentary supplies current evidence of relevance, but it does not establish that the same campaign can simply be exported. The transferable capability is learning and execution; local brands, claims and channels still require adaptation. [S4][S5]

North America’s reset

Management described a three-to-five-year reset at the September conference. The opportunity includes a stronger premium assortment, better promotion and improved commercial connections with retailers and digital platforms. A multiyear description is more credible than assuming inventory normalization alone restores growth. It also changes the timing of the investment case: spending can precede a reliable contribution for several periods. [S22]

The main risk is cannibalization without sufficient recruitment. A premium extension may move an existing Colgate buyer into a higher-priced product but require greater support, retailer spending and complexity. That can still create value, but only if incremental margin exceeds those costs. Stronger launch numbers without repeat purchase or regional profit would not establish success. The relevant confirmation is sustained positive volume and contribution across several reporting periods.

The absence of meaningful Q3 destocking makes the next clean consumption test more important. A future inventory restocking quarter could improve shipments without solving the underlying demand issue. Accordingly, both consumption and shipments should be tracked, alongside category growth and price gaps. A defensible turnaround assessment needs those bridges rather than relying on a single headline organic-sales inflection. [S5]

Hill’s and fresh nutrition

Hill’s organic sales increased 5.7%, with 1.8% volume. Official prepared remarks show 6.4% growth and 2.5% volume excluding the private-label exit. That is materially stronger than the prior flat underlying-volume picture. Cat, wet food and therapeutic products provide identifiable sources of improvement. The price-only characterization is now stale, although comparison normalization still needs to be completed. [S4]

The ending private-label drag is a temporary comparison benefit. Once it laps, adding it back indefinitely would overstate recurring growth. Investors should then evaluate the branded portfolio directly, including whether stronger wet and therapeutic demand improves utilization and contribution. Hill’s Q3 margin still declined 20 basis points, demonstrating that improved sales do not automatically create operating leverage. [S1]

Fresh food remains optionality rather than an explanation for current group growth. Management described U.S. fresh as insignificant in Q3 and emphasized a phased rollout into 2027. Prime100 provides Australian capabilities, but the full U.S. economics include manufacturing consistency, distribution, launch spending and professional adoption. Freshpet’s different model reinforces why category growth alone cannot establish an attractive capital return. [S5][S29]

Productivity and new tools

Revenue growth management, promotion analytics and AI-supported content can improve productivity. Potential mechanisms include fewer ineffective discounts, faster adaptation of creative material, better forecasting and improved availability. None of these benefits should be capitalized as a separate earnings asset without an attributable financial bridge. Adoption establishes that a tool is used; margins and cash establish whether the organization retained value.

Restructuring similarly creates an allocation choice. Savings can offset inflation, fund additional capabilities or raise earnings. Treating all gross savings as incremental profit while also forecasting higher support double counts the benefit. The growth algorithm needs a consistent bridge from sales through gross contribution, reinvestment, tax and cash. Management’s confidence is relevant, but the subsequent statements remain the test. [S4][S28]

Verdict: Demand is improving in breadth and quality. Emerging-market volume and Hill’s provide the clearest evidence; profitable U.S. conversion and fresh-food returns remain options that must earn their place in forecasts.

Financial Quality

Earnings occupy different points in the cycle: gross margins have recovered, while GAAP income still carries historical impairment and current restructuring. Reported earnings, company-adjusted operating measures and cash consequently answer different questions. GAAP preserves the consequences of acquisition and program decisions. Base Business measures improve operating comparisons but exclude real costs. Cash measures funding capacity, although timing, minority interests and compensation can separate consolidated cash from recurring common-owner economics. S2 [S3]

Five-year reconstruction

Dollars are millions except EPS and shares. The adjusted operating line uses the company’s disclosed reconciliations, rather than adding back impairment alone. Conventional FCF is operating cash less physical capex. [S3][S6][S7][S8][S9]

The normalized operating record is favorable but less spectacular than the GAAP recovery suggests. Base operating profit increased about 12% between 2021 and 2025 while revenue increased 17%. The 2022 cost shock damaged margins, subsequent pricing repaired them, and 2025 adjusted operating profit was essentially flat. EPS can grow faster through repurchases and below-operating-line changes. Calling the entire per-share algorithm organic operating compounding would therefore overstate the record.

Historical exclusions also differ economically. The 2022 reconciliation includes impairment, restructuring, acquisition costs and a land-sale gain; the 2023 operating bridge includes recall costs. A consistent adjusted series must remove gains as well as charges. The Q1 2023 filing’s $25 million product-recall adjustment is a reminder that product-quality risk has produced actual expense, rather than existing only in generic risk language. [S8][S35]

Debt rose with pet-capacity investment in 2022 and subsequently declined. Near-zero common equity reflects cumulative distributions, accounting adjustments and retained earnings, rather than demonstrating an absence of economic franchise value. Total equity includes subsidiary minorities; it must not be silently substituted for common equity in per-share book calculations. ROE and price-to-book are poor decision tools for this capital structure. [S3][S6][S7][S8][S9]

Company Financials was used for profile, statements, ratios, valuation and transcript cross-checks. Material discrepancies were rejected: its operating-income mapping does not consistently match filing operating profit, and its cash-flow mapping omits physical capex. An apparent FCF number equal to operating cash is unsuitable here. The reconstructed tables preserve filing definitions and period labels rather than accepting a coherent-looking data series that mixes them.

Current profitability and its cost

Q3 GAAP operating profit increased to $1.088 billion; Base operating profit was $1.117 billion. GAAP operating margin declined 30 basis points to 20.3%, while Base margin increased 20 basis points to 20.8%. The distinction is material: the quarter improved on the adjusted comparison, but reported margin did not expand. Nine-month Base margin was 21.2%, down 20 basis points. [S1][S2]

Management’s gross-margin bridge attributes approximately 300 basis points of pressure to materials, offset by 290 from productivity, 80 from pricing and 20 from mix. Below gross profit, advertising increased 130 basis points of sales, overhead efficiency provided 90 basis points and logistics cost 30. The resulting 70-basis-point increase in adjusted SG&A intensity absorbed most gross-margin improvement. These are management decompositions, not independently isolated causal effects. [S4]

Advertising was $775 million in Q3, or 14.4% of sales, versus $674 million and 13.1%. Nine-month advertising reached $2.286 billion. A strong gross line therefore does not establish that all productivity becomes shareholder profit. The company is simultaneously repairing demand, funding innovation and absorbing cost pressure. The investment question concerns the future contribution from that spending, not simply whether the gross margin is high. [S2]

Adjustments and cash conversion

FY2025’s $4.347 billion Base operating profit includes adjustments for $919 million impairment, $99 million ERISA operating expense, $13 million restructuring and $9 million acquisition costs. The total ERISA pretax earnings effect differs from its operating classification because pension and attorney-fee components sit in different lines. The disclosed reconciliation is preferable to a partial hand-built EPS adjustment. [S3]

The latest filing discloses $333 million nine-month SGPP pretax expense and $268 million attributable after-tax adjustment. The first-half filing reported $305 million pretax, while Q3 separately reports $30 million. Those rounded disclosures differ by $2 million from simple addition, exceeding ordinary rounding of three whole-million totals. No reconciliation is supplied in the reviewed passages. The difference is small relative to earnings, but precise program arithmetic should remain qualified rather than silently forcing the totals to agree. [S2][S10]

The EBITDA amount is an analyst proxy, not a company-reported measure. It combines Base EBIT with disclosed D&A; any overlap between excluded accelerated depreciation and total D&A would require a further refinement. EBIT and cash yield provide useful checks that avoid relying entirely on that proxy. Trailing Base EPS is approximately $3.89; adding rounded period EPS is approximate because weighted shares differ. [S2][S3]

Operating cash exceeds GAAP income partly because impairment is noncash and restructuring payments lag expense recognition. Trailing attributable GAAP income is approximately $2.053 billion, but consolidated cash includes minority cash. A direct ratio between those figures overstates the purity of common-owner conversion. Nine-month operating cash also includes a $177 million restructuring-and-termination adjustment net of cash, illustrating why future payments matter. [S2][S3]

Nine-month FCF increased 6.6%, from $2.358 billion to $2.513 billion. Subtracting the first-half statements gives standalone Q3 FCF of $1.037 billion versus $1.106 billion, down 6.2%. The release’s broad language about increasing FCF should not be read as establishing standalone-quarter growth. Actual program payments, working capital and tax timing can explain volatility; the decline still qualifies the prior acceleration narrative. [S1][S2][S10]

ROIC and omitted capital

Defined FY2025 normalized ROIC is approximately 45.7%, falling to 41.9% under a matched three-year research-capital sensitivity. This is an analyst calculation using 24% assumed tax and average total equity plus funded debt less cash, retaining goodwill and excluding operating leases. It is not directly comparable with Company Financials’ differently defined 25.7% GAAP ROIC. [S3][S6][S7]

The conventional denominator averages $7.397 billion in 2024 and $7.065 billion in 2025, or $7.231 billion. Base EBIT after assumed tax is $3.304 billion. On the same convention, GAAP EBIT produces about 34.7%. The large normalized return demonstrates attractive book economics, but not an acquisition-inclusive lifetime cash return or a directly observed spread over a precisely measured cost of capital.

The research sensitivity uses annual expense of $320 million, $343 million, $355 million and $366 million for 2022–2025. Three-year straight-line amortization begins after the spending year. Average reconstructed research capital is $703.7 million; 2025 amortization is $339.3 million. Replacing current expense and adding the matching asset lowers the return to 41.9%. Useful life, tax and asset overlap remain assumptions. The adjustment must affect both profit and capital. [S3][S7]

Advertising is a larger omitted-capital issue, with $2.703 billion expense in 2025. Some spending maintains current preference and some supports longer-lived assets; no public bridge establishes the split or useful life. Capitalizing all advertising mechanically would create false precision. Historical impairment is another distortion: restoring identified written-down amounts under a simple gross-capital sensitivity lowers the normalized return to about 36.8% before research capitalization. This is not a transaction IRR, but prevents a write-down from flattering interpretation of later returns.

Cash-funded buybacks do not mechanically reduce equity-plus-debt-minus-cash capital because cash and equity decline together. The more important distortions are expensed commercial assets, impairment, acquisition accounting and the operating-cash convention. Attractive returns survive reasonable sensitivities, but their magnitude should not be used to claim that every incremental investment earns comparable economics.

Liquidity and obligations

At September 30, cash was $1.527 billion, funded debt $7.716 billion and marketable securities $85 million, producing $6.104 billion net debt. That is approximately 1.19 times the EBITDA proxy. Commercial paper was $1.037 billion; its long-term classification depends on refinancing intent and capacity, not contractual permanence. Positive recurring cash and financing access matter more than the current ratio alone. [S2]

Material economic obligations include recognized leases and retirement liabilities, restructuring payments, supplier-finance balances and uncertain legal or tax claims. Year-end operating lease liabilities were $566 million. The aggregate net funded deficits across U.S. pensions, international pensions and other retiree benefits were approximately $1.283 billion. These are genuine claims despite being excluded from the headline funded-debt ratio; their cash timing and tax treatment differ from debt. [S2][S3]

Supplier-finance obligations of $218 million are already included in accounts payable. The company-defined negative working-capital ratio includes operating accruals; it does not prove that customers and suppliers alone finance inventory. Adding supplier finance a second time would overstate liabilities, while ignoring its growth would miss a cash-conversion sensitivity. [S2]

Research and advertising expensing is conservative for current income, while impairment estimates and recurring exclusions warrant separate skepticism. Audit and control opinions support reporting confidence but do not establish the best owner-earnings definition. Physical capital intensity is modest, while commercial reinvestment is substantial. Nine-month capex was 2.5% of sales, with approximately 3% expected annually; research and advertising represent additional recurring resources. [S2][S3]

Verdict: High margins, strong defined returns and moderate funded leverage support financial quality. Cash timing, subsidiary minorities, omitted commercial capital and real adjusted-out costs qualify its magnitude and valuation usefulness.

Capital Allocation

Management combines reinvestment, a rising common dividend, repurchases and balance-sheet flexibility. Nine-month operating cash of $2.913 billion less $400 million capex left $2.513 billion conventional FCF. Cash dividends of $1.308 billion and treasury purchases of $927 million consumed about 89% combined. Those dividends include distributions beyond common shareholders; $178 million option-exercise proceeds also distinguish gross repurchases from net cash returned. S2

Dividends, repurchases and issuance

The common dividend is $0.53 quarterly, or $2.12 annualized, consuming approximately 54% of guided Base EPS. Earnings cover it about 1.85 times. The current annualized common requirement is approximately $1.685 billion using September shares, comfortably below conventional FCF. The next declared payment is November 13 for October 20 record holders. [S19]

Calendar distinctions resolve the inherited dividend error. The company reports $2.06 paid per common share during 2025, while the equity statement records $2.08 declared. The issuer’s dividend history groups payments by their calendar year and includes a prior-December declaration in January’s ex-date cycle. Four dividends were declared in 2025; five in 2024. Consolidated dividends paid divided by common shares cannot reproduce the common rate because minority distributions contaminate the numerator. [S3][S19]

The increase from $0.52 to $0.53 was 1.9%. Its slower pace is an allocation observation, not a reliable reading of management’s private confidence. Repurchases, program payments and flexibility compete for the same cash. A long payment record can encourage discipline, but does not make the dividend inviolable under every conceivable liability or operating scenario.

Q3 disclosed repurchases averaged $89.70, while ending common shares fell to 794.9 million. The table includes 319,058 shares surrendered for employee elections; announced-program purchases were 3.361 million shares. Year-end-to-September shares declined about 0.8%. The current price exceeds the quarterly average, but a favorable short-term mark does not establish the lifetime return earned by repurchasing. [S2]

Stock compensation is an economic cost despite repurchases more than offsetting issuance. Expense was $141 million for nine months and approximately $169 million trailing. Using an economic deduction from cash is one way to recognize that cost; modeling full dilution is another. Deducting both full replacement cost and the same dilution would double count. An authorization alone is not a shareholder return, and gross buying should not be confused with net share reduction. [S2][S3]

Acquisitions and reinvestment returns

The acquisition record is mixed: repeated Filorga impairments contrast with pet-capacity and capability purchases whose standalone returns remain undisclosed. Identified charges were $571 million in 2021, $721 million in 2022 and $919 million in the 2025 Skin Health reporting unit. Their $2.211 billion gross sum is not a literal cash-loss percentage on the original deal because currency, reporting-unit scope and other accounting changed. It is strong evidence of repeatedly reduced purchased expectations. [S3][S8][S9]

The capital history also includes the Red Collar manufacturing-business purchase, finalized at $719 million, and the Nutriamo plant acquisition in 2022. These supported Hill’s production capabilities, including wet food. Excluding them while celebrating today’s modest capex would understate resources committed to the nutrition franchise. Current utilization gains can improve their return, but public consolidated results do not establish transaction-level IRRs. [S8]

Prime100 cost $301 million, or $293 million net of acquired cash, including $207 million goodwill and $64 million identified intangibles. Goodwill is neither total consideration nor a cash-return measure. Management reports strong growth, but follow-on launch, distribution and capacity costs must remain in any assessment of the wider fresh-food strategy. A smaller capability purchase reduces the scale of risk without eliminating execution uncertainty. [S2][S4]

The SGPP remains estimated at $350–550 million pretax, 80–90% cash. The prior productivity program incurred $228 million charges and reportedly generated about $125 million annualized pretax savings. That record supports execution credibility, but does not verify this program’s net return. Savings used to offset inflation or fund advertising cannot simultaneously be counted as incremental earnings. A proper scorecard needs gross savings, reinvestment, payments and retained cash. [S2][S3]

Incentives and insider behavior

Annual incentives weight Base EPS 40%, organic sales growth 40% and strategic initiatives 20%; long-term performance awards weight relative organic growth 50%, relative Base net-income growth 30% and cash productivity 20%, with a relative-TSR modifier. About 71% of nonemployee-director compensation was equity in 2025. These actual metrics are more informative than describing a generic margin-and-EPS plan. [S12]

Compensation discretion cuts both ways. The committee raised compensation EPS from $3.69 to $3.75 for specified tariff effects under discretion reserved when targets were set. It also reduced the three-year cash-productivity result from 133.6% to 115.7% to remove the artificial benefit of noncash charges depressing the denominator. The first adjustment relieved management of a cost owners bore; the second prevented an accounting windfall. Both belong in a balanced governance assessment. [S12]

The incentive structure favors consistent growth, cash productivity and shareholder returns, but no reviewed disclosure establishes an acquisition-level return hurdle. CEO ownership requirements are eight times salary. Those mechanisms support alignment while leaving questions about adjustment discretion and acquisition discipline. Awards based partly on relative net-income growth also reduce exclusive dependence on buyback-assisted EPS. [S12]

Wallace exercised and sold 322,042 shares across August 4–5. His direct holdings returned to 362,231 after each matched transaction. Cahill exercised and sold 4,170 shares: the displayed 32,543 holding followed exercise, and 28,373 followed sale. Reconstructing the pre-exercise balance gives 28,373, so the sequence does not establish the prior report’s claimed 13% reduction in his existing direct stake. Both reviewed filings show no marked 10b5-1 indicator, but neither identifies a bearish economic forecast. [S20][S21]

Insider conclusions apply to those specified filings, not an exhaustive five-year absence of open-market purchases. Grants, option exercises and tax withholding are distinct from open-market buying. The latest 10-Q’s absence of newly adopted or changed covered trading arrangements also does not mean no trades occurred. Personal liquidity and diversification motives remain unobserved. [S2]

Verdict: Routine cash allocation is sustainable, but advertising, restructuring and acquired capabilities need stronger capital-inclusive return evidence. Filorga weakens the historical acquisition assessment; current leverage and net share reduction provide offsets.

Changes and Headwinds — Last Two Years

Results reflect both external conditions and internal execution: currency and costs changed while productivity, pricing and commercial actions affected how much value was retained. The latest gross-margin bridge shows substantial material inflation rather than a simple commodity windfall. Conversely, reported revenue growth still benefits from currency. Neither an exclusively macro explanation nor an exclusively management-skill explanation fits the record. [S4][S5]

Operating environment and guidance

The 2024 margin recovery was followed by sharply slower organic growth and approximately flat adjusted operating profit in 2025. During 2026, volume improved while North America remained weak. The progression is demand repair after inflation-recovery pricing, rather than a continuation of the unusually high organic rates recorded earlier. Different comparison bases and portfolio changes must remain visible in that history. [S3][S6]

Guidance evolved meaningfully. The Q2 framework expected roughly flat gross margin and mid-single-digit Base EPS growth. Q3 changed gross margin to growth and Base EPS growth to 5–7%, while narrowing reported sales growth to 4–5%. Organic growth is now expected broadly in line with the nine-month 3.0% performance. This is a narrower operating expectation, not a promise that Q4 replicates Q3 in every region. [S1][S28]

Management expects elevated materials and logistics through Q4 and into early 2027. On the latest call, the approximate annual incremental-cost description returned to the original $300 million range after earlier discussion of possible relief. Freight can affect earnings faster than materials flowing through inventory. Spot oil alone is therefore an inadequate forecasting input; purchasing commitments, formulation, inventories and transport all affect realized costs. [S5]

Currency support diminished from the first half but did not disappear. Q3 benefited about one point overall, with a larger Latin American tailwind and negative translation in EMEA and Asia Pacific. The earlier blanket claim that second-half FX support would vanish was too strong. The correct distinction is less favorable and geographically uneven translation, alongside improving constant-currency demand. [S1]

Strategy, organization and reporting

The important operating changes are North America’s commercial reset, the phased U.S. fresh-food rollout and the redeployment of restructuring resources. Management’s 2030 strategy emphasizes science-based premium innovation, demand generation and analytics. Those initiatives are actions and hypotheses; the independent outcome test remains sustained volume, contribution and cash. [S4][S22]

The September discussion explicitly framed North America over three to five years. Current leadership materials identify Noel Wallace as chairman and CEO, Stan Sutula as CFO and Claire Ross as EVP of Investor Relations. The changes in commercial leadership and investor interface warrant monitoring, but personnel changes alone do not establish organizational instability. Responsibility and repeated operating outcomes are more decision-useful. [S22][S34]

Segment reporting changed materially, while the latest filing reports no newly effective accounting pronouncement with a material financial-statement impact. Skin Health was consolidated into North America effective July 2024, then moved into the new EMEA division in 2026. EMEA combined Europe with Africa/Eurasia excluding Russia and Belarus; those countries moved to Asia Pacific. Historical geographic information was recast without changing consolidated results. [S2][S27][S30]

Consequently, a long regional trend assembled from unrecast reports can be misleading. The reporting move also does not remove Skin Health’s economic exposure. Brands, assets and obligations remain consolidated regardless of the management line under which they appear. This is particularly relevant when interpreting both North American repair and EMEA pricing.

Transactions, tax and litigation

Prime100’s April 2025 acquisition and the completion of its purchase allocation are the principal recent transaction developments. No transformative acquisition is necessary for the current growth case. The next capital question is operational deployment and return, including fresh nutrition, rather than assuming another deal solves demand. [S2][S38][S39]

Legal developments are financially more significant than the prior report suggested. Pending talc cases increased from 453 at year-end to 561 in September, with 78 additions and 42 resolutions in Q3. The filing describes recent settlements as immaterial but expressly limits the interpretation of estimated possible losses. ERISA settlement attorney fees and costs of $99 million were paid by the company, while the plan funded the remaining settlement. [S2]

Tax developments also require scale discipline. The current filing says 2025 U.S. tax legislation did not materially affect nine-month 2026 financial statements. Brazilian disputes remain active, including adverse appeal developments; a management defense position is not an independent probability estimate. The relevant questions are recognized reserves, cash timing, credible ranges and any change in legal precedent, rather than treating all disputed assessments as immediately payable. [S2]

The business environment changed materially: broader global demand now coexists with persistent inflation, a longer U.S. repair and greater visibility of legal obligations. The strongest improvement is volume and margin resilience. The principal unresolved changes concern the retained return on support and the timing of cash costs.

Verdict: Global execution improved under difficult conditions. The upgrade is supported, while the U.S. timetable, cost environment and legal tail prevent declaring the operating reset complete.

Risk Analysis

The stock can decline through slower volume, a more expensive U.S. repair, weaker cash conversion or a lower valuation assigned to defensive earnings. These mechanisms do not require the products to become obsolete. Lower cash growth and a higher required return can interact, producing a substantial equity loss despite continuing revenue and dividends. [S1][S2][S13]

Likelihood labels are analyst judgments, not statistically estimated probabilities. Talc is deliberately not assigned a spurious precise probability. Case counts describe workload and potential exposure, but do not reveal claim quality or expected settlement severity. The combination of more cases and limited current cash expense is therefore neither proof of impending catastrophe nor adequate evidence of negligible risk.

A simple operating stress illustrates ordinary earnings sensitivity. At roughly $21.3 billion revenue, a 100-basis-point reduction in retained operating margin is about $213 million pretax. At an assumed 24% tax rate, that is approximately $162 million, or $0.20 per current share before other effects. A modest margin disappointment can therefore offset a meaningful portion of expected EPS growth. The calculation is a sensitivity, not a forecast.

North America represents around 17% of current sales, so its weakness need not destroy consolidated economics. The more plausible adverse mechanism is prolonged support spending with insufficient recruitment, reducing cash available elsewhere. International growth is an offset, but it brings currency and local-political exposure. A simultaneous slowdown in several profit pools would make the repair harder to finance without sacrificing distributions or other investment. [S1][S2]

Catastrophic investment loss could arise from widespread product harm or legal liabilities exceeding insurance and ordinary cash-generation capacity. The disclosed $0–225 million reasonably possible loss range above accruals covers estimable matters and is not a maximum exposure. Coverage can face exclusions, limits, carrier disputes and exhaustion. Recent immaterial settlements cannot be converted into a reliable ceiling for immature claims. [S2]

Total loss is remote under current financial conditions, but a plausible path combines severe franchise damage, extraordinary liabilities and loss of financing access. Moderate funded leverage and recurring consumption make ordinary refinancing-driven failure unlikely. They do not eliminate unbounded-liability scenarios. Public evidence cannot support a precise ruin probability, and the dividend record is not a legal protection for equity. [S2][S3]

A large noncatastrophic loss needs much less. EPS of $3.80 at 18 times implies approximately $68 before dividends. That scenario assumes a functioning business with weaker growth or a lower premium, not insolvency. The most relevant protection is retained cash growth and valuation discipline, rather than reliance on the defensive label.

Verdict: Ordinary financial resilience is strong. Execution and valuation can still create substantial downside, while product trust and litigation define the more severe tails.

Valuation Discussion

The reference is $95.29 at October 30 and 794.920513 million reported September shares. Market capitalization is approximately $75.748 billion. Adding $6.104 billion net debt and $352 million book noncontrolling interests gives $82.204 billion enterprise value. This conventional NCI amount is a book-value proxy, not a market appraisal of minority claims. Operating leases are excluded, with their expense retained in earnings. [S2][S13]

Guidance implies approximately $3.87–3.95 Base EPS, using 5–7% growth on $3.69. That arithmetic is an analyst calculation applied to management’s forecast. There is no retained company-issued 2027 EPS guidance. GAAP earnings remain relevant to capital stewardship, but their impairment and restructuring distortions make a bare trailing P/E a weak standalone valuation tool. [S1][S3]

Peers and own-history context

PG’s $161.57 price divided by $7.00 guided Core EPS gives 23.1 times. CHD’s $107.23 divided by the release reconciliation’s $3.76 gives 28.5 times. Its rounded approximately 7% growth description should not replace that explicit dollar forecast with a newly manufactured precise EPS estimate. Fiscal periods and adjustment policies limit direct rankings. [S15][S16][S17][S18][S25][S26]

CL’s premium over PG cannot rest on a unique-execution assertion. Equally, CHD’s higher multiple does not prove CL is cheap: growth, category mix, acquired capital and cash quality differ. Premium oral and therapeutic nutrition deserve category-specific assessment, while a sum-of-parts model would also need credible Corporate cost allocation. Assigning Hill’s a specialist multiple and leaving all research and support in an unvalued corporate bucket would overstate group value.

Own-history context was rebuilt on a consistent price-times-ending-shares basis. Year-end price/operating-cash multiples were approximately 21.6x, 25.6x, 17.5x, 18.0x and 15.1x for 2021–2025, a median near 18.0x versus 17.35x today. This differs modestly from supplied ratio fields because share conventions differ. The historical sample supports a full but not unprecedented cash-flow valuation; it does not establish a reversion target. [S3][S6][S7][S8][S9][S13]

Normalized common-owner cash

Conventional FCF is not entirely attributable to common owners. Deducting $169 million trailing stock compensation and $150 million trailing NCI dividends declared produces a $3.470 billion cash proxy. The minority figure is reconstructed as $157 million annual declarations plus $46 million current nine months less $53 million prior nine months. Declarations are observable but are not a fully reconciled cash-paid schedule. [S2][S3]

The DCF instead assumes $3.3 billion normalized owner cash. The approximately $170 million reduction from that proxy provides a cautious allowance for conversion and remaining program-payment uncertainty. It is close in size to the latest $177 million restructuring-related cash-flow adjustment, but is not asserted to be an exact recurring cost. It also avoids capitalizing the best recent consolidated cash result indefinitely.

This convention requires care. Actual restructuring payments already reduce reported operating cash; subtracting the same payments again would double count. Conversely, a temporary accrual-supported conversion benefit should not recur perpetually in a model. A dollar-for-dollar minority deduction also differs from using attributable earnings because subsidiaries can retain cash. These uncertainties support a starting range around $3.2–3.5 billion rather than a false point estimate of economic owner earnings.

Explicit operating scenarios

These are analyst assumptions for 2027, not company guidance. They begin around $21.3 billion 2026 revenue, broadly consistent with the current annual sales framework. Ordinary taxes are assumed around 24%, interest and minority claims remain, and no transformative acquisition is included. [S1][S3]

The central case requires global momentum and a diminishing U.S. drag, not an immediate regional boom. The bull case requires profitable North American recovery, sustained Hill’s demand and better support productivity. The bear case retains valuable brands while weaker conversion reduces earnings. These assumptions connect revenue, margins and reinvestment instead of applying different multiples to an unchanged EPS number.

Ten-year cash valuation and embedded expectations

The equity-cash model starts at $3.3 billion, grows aggregate owner cash and holds the current share denominator fixed. It does not also add buyback-driven per-share growth. Cash spent on repurchases is a distribution of the modeled stream, not an extra operating return. The terminal multiple applies to year-ten cash and the model includes annual cash distributions; net debt is not subtracted again because interest and creditor claims are already reflected in equity cash.

These are scenario outputs, not price targets. At 4% cash growth and 20 times terminal cash, changing the required return from 7.5% to 9.0% changes value from approximately $94 to $84. Changing starting cash from $3.3 billion to $3.5 billion raises the central output to approximately $96. Thus the draft’s central valuation near the quotation depended materially on its more generous cash starting point.

At 8% required return and 20 times terminal cash, the current market capitalization requires about 4.6% aggregate owner-cash growth annually for ten years from the selected starting point. Approximately 63% of central model value comes from the terminal amount. A 20-times cash terminal multiple at an 8% required return is broadly consistent with continuing growth near 2.9% under a perpetuity interpretation, so it embeds enduring franchise economics rather than a no-growth liquidation.

The current price correctly recognizes resilient demand, high margins, moderate debt and improved global volume. The fragile assumptions are cash normalization, profitable U.S. conversion and the durability of the terminal premium. A defensible central value does not create a large error allowance. Equally, modestly lower prices would not compensate for a fundamental break in trust or a large legal liability; those require changed cash assumptions.

Verdict: The quotation is supportable if improved demand becomes durable common-owner cash. Its protection against weaker conversion or lower terminal economics is limited, and small cash-definition changes materially affect the apparent upside.

Variant Perception

A current public analyst summary shows a Buy consensus and a mean target around $98.15. It is a dated sentiment indicator: not every forecast necessarily incorporated the latest release. The inferred prevailing view is that global oral leadership, emerging-market demand and Hill’s justify premium valuation. No consensus dataset establishes what probability investors assign to the U.S. reset or to marketing returns. [S24]

The strongest bull case is now supported by broader volume, better Hill’s demand, gross-margin resilience and lower net debt. Global capabilities are working in several regions, and a smaller North American drag could improve the consolidated algorithm without extraordinary category growth. The strongest bear case is that U.S. weakness persists without inventory noise, increased support absorbs productivity, and owner cash is weaker than the consolidated headline. Current competitors make both arguments more demanding: Colgate is strong, but its premium opportunities are actively contested. [S2][S4][S15][S16][S17][S18]

Investor questions center on advertising conversion, shipment-versus-consumption differences, productivity offsets, cost duration and Hill’s underlying volume. Kevin Grundy’s Q2 question challenged the return on elevated advertising; Rob Moskow asked about persistent tracking discrepancies. In Q3, Chris Carey tested inventory effects, Dara Mohsenian examined cost and margin, and Lauren Lieberman asked about overhead efficiency. Those questions identify the right uncertainties; management’s answers remain claims to verify against subsequent results. [S5][S36]

Four assumptions carry most of the debate: global volume persists after comparison normalization; U.S. support produces profitable recruitment; productivity offsets inflation after reinvestment; and resulting owner cash sustains a premium terminal valuation. The bull case fails when the first three repeatedly fail to reach the fourth. The bear case fails if clean volume, retained margins and cash improve without another escalation of commercial or program costs.

The factor model

The factor model, dated October 30, has R-squared 0.5856 and adjusted R-squared 0.5772. Its principal supplied exposures are Consumer Staples sector +0.7682, LowVolatility +0.5047, Market +0.3637, BetaFactor −0.5089, OilPrice −0.2433 and InterestRate −0.1270. Momentum is +0.0197 and Quality +0.0098. These are internal statistical diagnostics, not cited fundamental evidence or legal industry classifications. [S14]

The pattern is consistent with defensive return behavior. It does not establish investor crowding, a lower observed cost of equity or a guaranteed response to rates. The oil coefficient is not an estimate of EPS lost per dollar of oil. Factor definitions, scaling, windows, standard errors and stability tests would be necessary before converting coefficients into precise stress returns.

Residual volatility is 0.128889 and residual Sharpe 0.399363 as supplied. Their horizon conventions are not independently established here. The alpha value is not annualized, and residual momentum is not relabeled a six-month price return. Approximately 41.4% of in-sample variation remains unexplained; that is not a causal allocation of any particular share-price move to company news.

The peer price comparison supplies a separate reality check. CL underperformed PG and CHD between reports despite operating improvement. That observation challenges a narrative of exceptional relative reward, while not proving undervaluation. Different companies can recover at different times, and stronger growth can rationally earn a higher multiple. The differentiated question remains the return on incremental support and the cash owners retain.

Verdict: Global repair has advanced further than U.S. repair. The useful disagreement concerns conversion and duration, rather than whether the legacy franchise exists or whether defensive return exposures establish value.

Fact vs. Interpretation

Cross-company research-capital hypotheses were tested as methods rather than imported numerical facts. Research-intensive software, semiconductor and biotechnology examples do not determine CL’s research life or economic return. Its matched sensitivity leaves high returns, while commercial investment and written-down acquired capital remain additional issues. The counterexamples in which research capitalization barely changes returns show why the direction and magnitude must be calculated rather than assumed.

Bank fair-value-capital observations are not a directly applicable CL operating thesis. Long-duration third-party brand-license economics also require an identified matching contract before applying royalty and termination-cost adjustments. Neither mechanism should be inserted simply because it appears useful elsewhere. The applicable broader question is whether all resources committed to a cash stream are retained in return analysis.

Two company-specific accounting corrections survive verification: common dividends must be separated from consolidated distributions and calendar bases; acquisition normalization must retain committed capital. A third comes from the insider sequence: matched exercise-and-sale holdings must be compared with reconstructed opening ownership, not an intermediate post-exercise balance. The conclusion is an arithmetic distinction, not an inference about motive. [S3][S19][S20][S21]

Verdict: The record supports operating improvement and attractive economics. It does not establish advertising causality, completed U.S. repair, precise acquisition IRRs or a negligible legal tail.

Open Questions

The highest-value question remains the U.S. purchase-conversion bridge. Management reports stronger brand metrics and early share progress, while regional volume and profit remain weak. A consistent reconciliation among shipments, tracked consumption, untracked channels, price gaps, premium mix and retained contribution would discriminate between timing and persistent demand problems. Neither the bullish temporary-noise explanation nor structural-decline language is fully established without it. [S2][S5]

Advertising needs a multi-period return test. What portion recruits new households, what portion maintains existing share, and what persists after campaign intensity stabilizes? The public record lacks incremental contribution by cohort. Aggregate volume and profit are useful outcomes but cannot identify the return from one extra advertising dollar. A fair test allows launch timing while requiring persistent improvement.

The SGPP needs a complete cash-return bridge: gross savings, reinvestment, actual payments, remaining commitments and retained benefit. The latest lower charge quarter is favorable, but the unchanged envelope does not establish the final return. The small mismatch between cumulative quarterly disclosures also needs reconciliation before precise charge-cadence conclusions are drawn. [S2][S10]

Hill’s needs clean branded-volume comparisons after private label exits the calculation. Fresh should be separately discussed once material, including launch support, service and production economics. Otherwise mature therapeutic growth and early fresh-food spending can become blended into a misleading single growth narrative. Current management commentary explicitly describes fresh as a small contribution. [S4][S5]

Common-owner cash requires better disclosure of minority cash distributions and recurring working-capital needs. The $150 million trailing minority declaration bridge is more observable than an unsupported allowance, but it is not an exact cash-paid schedule. The $3.3 billion normalized starting point remains an assumption, with valuation sensitivity deliberately visible.

Legal monitoring should focus on claim quality, trial outcomes, settlement dispersion, reserves and recoverable insurance, rather than case counts alone. The disclosed possible-loss range is incomplete for outcomes that cannot be estimated. A reconciled global market-size denominator and acquisition-level return schedules are also missing. None of these uncertainties should be filled with inherited analyst confidence. [S2][S8]

What Must Be True

The following thresholds are analyst monitoring rules, informed by current disclosures. They are not company targets, and a mechanical threshold should be reconsidered if product scope, accounting definitions or reporting boundaries change. The earlier wrong gross-margin comparator demonstrates why an explicit test can still be invalid. [S1][S27]

Bull tests

Global demand must remain broader than inflation recovery. A useful confirmation is consolidated organic volume around 1.5% or better over several quarters, alongside positive Hill’s branded volume after the private-label comparison ends. Two consecutive quarters at zero or negative global volume despite sustained support would materially weaken the repaired-demand interpretation. The latest 1.7% consolidated and 2.5% ex-exit Hill’s results provide the premises, not proof of permanence. [S1][S4]

North America must improve economically. Two consecutive quarters of positive organic volume and nonnegative organic sales, with stable or improving operating contribution, would be stronger evidence than isolated share gains. Continued negative volume through the first half of 2027 without meaningful inventory contraction would materially undermine the expected conversion of premium innovation and support. A restocking-driven shipment bounce without consumption improvement would not pass. [S2][S5][S22]

Margin resilience must survive the realized cost environment. Q4 should be assessed against the correct year-ago comparison and the full-year promise of higher gross margin. A material guide shortfall, followed by a 2027 framework requiring still-higher support simply to stabilize earnings, would weaken the bull case. Stable advertising intensity is helpful, but profitable growth can justify additional spending; retained contribution is the governing test. [S1][S4][S5]

Cash must follow earnings after physical investment, compensation and actual program payments. Normalized common-owner cash persistently below approximately $3.2 billion would challenge the selected $3.3 billion starting point. A one-year working-capital fluctuation alone is insufficient; repeated cash shortfalls without a credible reversal bridge matter more. Growing accruals, supplier financing or minority retention must not substitute indefinitely for distributable cash. [S2][S3][S10]

Bear tests

The bear case requires poor retained returns on support, not merely high advertising. It strengthens if support stays near or above current intensity while global volume slows, U.S. contribution remains weak and adjusted operating margin declines. It weakens if demand and cash persist with stable support intensity. The current quarter already provides contrary evidence to an inevitable margin reversal and a Hill’s price-only thesis. [S1][S2][S4]

The restructuring concern requires actual overrun, extension or inadequate net benefit. A program remaining within $350–550 million, with accruals running down and savings supporting service, demand and cash, would challenge the claim that exclusions mainly conceal recurring inefficiency. Another material expansion without improved retained economics would strengthen it. Charges and payments must be scored separately rather than extrapolating the first-half expense rate. [S2][S10]

The competitive concern requires evidence that rivals are taking economically meaningful demand. Strong Haleon or Nestlé category growth alone does not establish Colgate share loss, just as Colgate volume growth alone does not establish gains. The test is persistent relative demand and retained contribution on comparable product and geographic scopes. Competitor results are a challenge to the unique-execution narrative, not a shortcut to a predetermined bearish conclusion. [S15][S16][S17][S18]

Current scorecard and catalysts

The correct Q3 comparison contradicts the prior near-term margin deterioration expectation. Hill’s positive volume challenges its earlier price-only characterization. North American weakness and elevated support remain confirmed; advertising causality, net restructuring returns, owner-cash normalization and legal exposure remain open. The prior accumulation range was reached, but that price outcome does not prove the operating thesis. [S1][S2][S4][S13]

The principal decision catalysts are Q4 realized costs and cash payments, initial 2027 guidance, clean Hill’s comparisons and repeated U.S. volume-and-contribution evidence. Positive confirmation requires those outcomes to align without another material escalation in program cost. Negative confirmation would be persistent demand weakness combined with weaker cash or a changed legal tail. These are more consequential than whether a single quarterly EPS number beats an undisclosed consensus.

Verdict: The global operating bear case has lost evidence, while the U.S. and cash-conversion questions remain decisive. Future judgment should follow matched demand, profit and cash outcomes, anchored to the verified Q3 results, S1, quarterly filing, S2 and prepared management remarks, S4.

Public source appendix

• S1: Colgate-Palmolive Q3 2026 earnings release — Primary company earnings release and reconciliations; published 2026-10-30; October 30 guidance; Tables 1–8; divisional growth and profitability; market-share methodology
• S2: Colgate-Palmolive Q3 2026 Form 10-Q — Primary SEC quarterly filing; published 2026-10-30; Cover; statements pp. 2–6; Notes 4–5, 10–14; MD&A pp. 31–53; repurchases p. 58; trading arrangements p. 59
• S3: Colgate-Palmolive FY2025 Form 10-K — Audited primary SEC annual filing; published 2026-02-23; Item 1; operating reconciliation pp. 32–36; statements pp. 70–74; Notes 4–5, 8, 10, 14, 16–18
• S4: Colgate-Palmolive Q3 2026 prepared management remarks — Primary prepared management commentary; published 2026-10-30; Overview and margin bridge pp. 1–3; divisional commentary pp. 3–6; Hill’s ex-private-label figures pp. 5–6; guidance
• S5: Colgate-Palmolive Q3 2026 earnings Q&A; Company Financials cross-check — Management statements in third-party transcript, cross-checked against Company Financials; published 2026-10-30; Carey inventory exchange; Mohsenian costs and advertising; Lieberman overhead; Hill’s and fresh-food discussion; Moskow inflation exchange
• S6: Colgate-Palmolive FY2024 Form 10-K — Audited primary SEC annual filing; published 2025-02-13; MD&A GAAP and Base operating reconciliations; audited financial statements; balance sheet, cash flow and share data
• S7: Colgate-Palmolive FY2023 Form 10-K — Audited primary SEC annual filing; publication date unavailable; Operating reconciliation; audited statements; Note 17 research and advertising cohorts; capital and share disclosures
• S8: Colgate-Palmolive FY2022 Form 10-K — Audited primary SEC annual filing; publication date unavailable; MD&A $721m Filorga impairment and operating reconciliation; Note 3 Red Collar and Nutriamo; audited statements and capex
• S9: Colgate-Palmolive FY2021 Form 10-K — Audited primary SEC annual filing; published 2022-02-17; MD&A operating reconciliation and $571m impairment; audited statements; physical capex, shares and compensation
• S10: Colgate-Palmolive Q2 2026 Form 10-Q — Primary SEC quarterly filing; published 2026-07-31; Cash-flow statement p. 5; Note 5 program charges and payments pp. 9–10; MD&A non-GAAP reconciliation and liquidity
• S11: Colgate-Palmolive Q1 2026 Form 10-Q — Primary SEC quarterly filing; published 2026-05-01; MD&A sales components; financial statements; restructuring expansion and segment realignment
• S12: Colgate-Palmolive 2026 proxy statement — Primary SEC proxy filing; published 2026-03-25; Director equity compensation; CD&A pp. 28–45; annual weights p. 38; tariff adjustment; long-term weights pp. 42–43; cash-productivity adjustment and ownership requirements
• S13: CL unadjusted daily price history; Company Financials cross-check — Third-party market data and analyst calculations; publication date unavailable; October 30 close and August–October history; Company Financials unadjusted 1,256-observation series, October 29, 2021–October 30, 2026; analyst extrema, year-end prices and returns
• S14: the factor model — October 30, 2026 snapshot — Supplied internal statistical diagnostic, not fundamental evidence; published 2026-10-30; Supplied exposures, residual signals and diagnostics; estimation conventions not fully supplied
• S15: P&G fiscal 2027 first-quarter results — Primary peer earnings release; published 2026-10-22; July–September sales bridge; Health Care volume; Core EPS; fiscal-2027 $6.89–7.11 guidance and $7.00 midpoint
• S16: Church & Dwight Q3 2026 results — Primary company press release distributed through Nasdaq; published 2026-10-30; Issuer-distributed release: organic sales and volume; margins; adjusted EPS; forecast reconciliation showing $3.76 annual adjusted EPS
• S17: Haleon Q3 2026 trading statement — Primary competitor trading statement; published 2026-10-29; Category table: Oral Health £930m and 8.8% organic growth; group price and volume/mix
• S18: Nestlé nine-month 2026 sales — Primary competitor sales release; published 2026-10-22; Q3 category table and Petcare commentary: 5.3% organic growth, 4.3% real internal growth; cat and therapeutics
• S19: Colgate-Palmolive common-dividend history — Primary issuer dividend records; publication date unavailable; September 17 declaration, October 20 record/ex-date, November 13 payment; quarterly rates and calendar payment totals
• S20: Noel Wallace August 2026 Form 4 — Primary SEC insider transaction filing; published 2026-08-06; Tables I–II: August 4–5 matched exercises and sales; holdings; option expiration; footnotes and plan indicator
• S21: John Cahill August 2026 Form 4 — Primary insider transaction filing on issuer website; published 2026-08-07; August 6 matched 4,170-share exercise and sale; intermediate and final holdings; footnotes and unchecked plan indicator
• S22: Colgate-Palmolive September 2026 Barclays conference transcript — Third-party transcript of management statements; published 2026-09-09; North America three-to-five-year reset; premium innovation; couponing, channels, emerging markets and capabilities
• S24: CL quotation and analyst-summary cross-check — Third-party market and consensus summary; publication date unavailable; October 30 close; annual range; Buy consensus and $98.15 mean target; older share count identified and excluded
• S25: P&G daily price history; Company Financials cross-check — Third-party market prices and analyst calculations; publication date unavailable; October 30 close $161.57; matched August 21–October 30 unadjusted series and analyst return calculation
• S26: Church & Dwight daily price history; Company Financials cross-check — Third-party market prices and analyst calculations; publication date unavailable; October 30 close $107.23; matched August 21–October 30 unadjusted series and analyst return calculation
• S27: Colgate-Palmolive March 2026 segment-realignment Form 8-K — Primary SEC material-event filing; published 2026-03-17; Item 8.01: EMEA formation, Skin Health transfer, Russia/Belarus transfer, recast history and no consolidated impact
• S28: Colgate-Palmolive Q2 2026 prepared management remarks — Primary prepared management commentary; published 2026-07-31; Margin and tariff-refund bridge p. 3; North America; EMEA negative pricing attributed to Skin Health; Hill’s private-label adjustment; prior guidance
• S29: Freshpet Q2 2026 Form 10-Q — Primary competitor SEC quarterly filing; publication date unavailable; Business and MD&A: fresh-food production, distribution, retail refrigerators, investment and operating costs
• S30: Colgate-Palmolive Q2 2024 Form 10-Q — Primary historical SEC quarterly filing; published 2024-07-26; Segment note: Skin Health reporting realignment effective July 1, 2024
• S31: P&G operating portfolio and major brands — Primary competitor investor materials; publication date unavailable; Health Care segment: oral-care product categories and Crest/Oral-B brands
• S32: Haleon March 2026 investor factsheet — Primary competitor investor materials; publication date unavailable; Oral Health category and Sensodyne, parodontax and Polident brand portfolio
• S33: Mars Petcare operating portfolio — Primary competitor company materials; publication date unavailable; Royal Canin and science-backed nutrition and therapeutic products
• S34: Colgate-Palmolive current leadership team — Primary current company leadership materials; publication date unavailable; Wallace, Sutula and Ross roles and biographies
• S35: Colgate-Palmolive Q1 2023 Form 10-Q — Primary historical SEC quarterly filing; publication date unavailable; MD&A operating-profit reconciliation: $25m product-recall costs
• S36: Colgate-Palmolive Q2 2026 earnings Q&A; Company Financials cross-check — Management Q&A and investor questions in third-party transcript, cross-checked against Company Financials; published 2026-07-31; Kevin Grundy advertising-return question around 36 minutes; Rob Moskow tracking and shipment question around 44 minutes
• S38: Colgate-Palmolive Q2 2025 Form 10-Q — Primary historical SEC quarterly filing; published 2025-08-01; Acquisition note and Prime100 transaction; financial and operating disclosures
• S39: Colgate-Palmolive Q1 2025 Form 10-Q — Primary historical SEC quarterly filing; published 2025-04-25; MD&A Prime100 agreement, regulatory approval and anticipated second-quarter closing